Liberum Capital reaffirmed their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note issued to investors on Monday, June 5th. Liberum Capital currently has a GBX 5,500 ($70.07) target price on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued research reports about the stock. BNP Paribas reiterated a neutral rating and issued a GBX 5,300 ($67.52) price objective on shares of AstraZeneca plc in a research note on Monday, April 3rd. HSBC Holdings plc reiterated a reduce rating and issued a GBX 4,200 ($53.51) price objective on shares of AstraZeneca plc in a research note on Friday, May 5th. Shore Capital restated a sell rating on shares of AstraZeneca plc in a research note on Wednesday, May 10th. J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a research note on Thursday, May 11th. Finally, Berenberg Bank raised their target price on shares of AstraZeneca plc from GBX 5,670 ($72.24) to GBX 5,850 ($74.53) and gave the stock a buy rating in a research note on Wednesday, May 17th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of GBX 5,171.80 ($65.89).
AstraZeneca plc (LON:AZN) traded down 0.30% during trading on Monday, hitting GBX 5400.00. 1,715,433 shares of the stock traded hands. The firm has a 50-day moving average price of GBX 5,134.14 and a 200 day moving average price of GBX 4,718.55. The company’s market cap is GBX 68.36 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.
TRADEMARK VIOLATION WARNING: This story was posted by BBNS and is the sole property of of BBNS. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://baseballnewssource.com/markets/liberum-capital-reiterates-buy-rating-for-astrazeneca-plc-azn-updated-updated/942489.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.